AIM
INSY

Acrospire Investment Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Acrospire Investment Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,909
Closed -$41K – 2739
2017
Q1 		$41K Sell
3,909
-12,897
-77% -$137K 0.03% 1127
2016
Q4 		$155K Sell
16,806
-8,689
-34% -$98.2K 0.06% 576
2016
Q3 		$301K Buy
25,495
+8,400
+49% +$128K 0.2% 22
2016
Q2 		$221K Buy
17,095
+11,095
+185% +$162K 0.16% 41
2016
Q1 		$96K Buy
+6,000
New +$114K 0.07% 349

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's INSY Position: Q2 2017 in Review

Acrospire Investment Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 3,909 shares — an estimated $41K sold.

Acrospire Investment Management first reported a position in INSY in Q1 2016 and held it in 5 quarters. The position peaked at $301K in Q3 2016. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • Acrospire Investment Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3,909 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $41K.
  • Acrospire Investment Management first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Insys Therapeutics, Inc. position peaked at $301K in Q3 2016.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.